- MarketWatch•5 days ago
Harry Boxer sums up what the charts are telling him about these four stocks.
- Investor's Business Daily•6 days ago
Shares of biotech leader Supernus Pharmaceuticals briefly broke out Tuesday, but struggled to remain above that key level of support.
- Investopedia•18 days ago
Supernus’ epilepsy drug Trokendi XR got FDA label expansion for use as a migraine prevention drug.
SUPN : Summary for Supernus Pharmaceuticals, Inc. - Yahoo Finance
Supernus Pharmaceuticals, Inc. (SUPN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||32.50 - 32.95|
|52 Week Range||14.14 - 33.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||18.56|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|